Dr Thomas commented regarding the Kryobulin licence application that despite precautions being taken, "the risk of transmission of serum hepatitis can only be diminished and not completely eliminated. Linked evidence MHRA0033322_060 - Summary and report on Kryobulin for product licence application - 01 Jan 1973 Chronology Information Date: 1 January 1973 Chapter/issue Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Dr Thomas commented regarding the Kryobulin licence application that despite precautions being taken, "the risk of transmission of serum hepatitis can only be diminished and not completely eliminated.
Chronology Information
Date:
Documents
MHRA0033322 060 Summary and report on Kryobulin for product licence application 01 Jan 1973